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1. INTRODUCTION
Botulinum toxin, a complex protein produced
by the anaerobic bacterium Clostridium botulinum,
is widely recognised as the most potent biological
poison. It was earlier known only as a causative
agent of a serious and often fatal disease known
as botulism, acquired through ingestion of contaminated
food.
Botulism is a rare but serious paralytic illness,
when the toxin causes paralysis by blocking the
presynaptic release of acetylcholine at the neuromuscular
junction1. Botulinum toxin is a very hazardous natural
compound which may be misused as biological
weapon as well as the instrument of bioterrorism2.
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ABSTRACT
Botulinum toxin is a group of seven homologous, highly poisonous proteins isolated from
fermentation of the anaerobic bacterium Clostridium botulinum, which naturally occurs in soil
and can grow on many meats and vegetables. Botulinum toxin causes neuromuscular disorder
called botulism, which is a potentially lethal disease. There are three types of botulism: Food,
wound, and infant botulism. It can lead to death unless appropriate therapy is done. Due to the
severity and potency of botulinum toxin, its importance as a biological weapon is of major
concern to public health officials. Nevertheless, botulinum toxin is also medicament.
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Pharmacological properties of botulinum toxin can
be utilised in current medicine. Advantage can be
taken of its neuromuscular blocking effect to alleviate
muscle spasm due to excessive neural activity of
central origin, or to weaken a muscle for therapeutic
purposes. In therapeutic applications, very small
quantities of botulinum toxin type A are injected
directly into the selected muscles. Botulinum toxin
can be considered as the instrument of terrorism
or instrument of biomedicine3. Both aspects of botulinum
toxin utilisation are discussed. For the past ten
years, enormous progress has been made in
understanding the action of botulinum toxin at the
molecular level, which has opened up the possibility
for rational studies of its mechanism of action and
active site inhibitor design.
SHORT COMMUNICATION
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2. BACTERIUM CLOSTRIDIUM
BOTULINUM
Clostridium botulinum is the name of a group
of bacteria commonly found in soil. These rod-
shaped microorganisms grow best in low-oxygen
conditions. The bacteria form spores which allow
them to survive in a dormant state until exposed
to conditions that can support their growth. There
are several serologically distinct botulinum toxins,
which have slightly different specific effects. These
toxins are designated by the letters A through G;
only types A, B, E and F cause illness in human
beings4.
2.1 Botulinum Toxin
All serologically different botulinum toxins are
synthesised as a single-chain polypeptides with a
molecular weight5 of approx. 150 kDa. The complete
amino acid sequences for the various serotypes are
known6 and regions of sequence homology among
the serotypes suggest that all employ similar mechanism
of biological action7. In the single-chain form, toxins
have relatively little potency as neurotoxins. Neurotoxic
activation requires a two-step modification in the
tertiary structure of the protein8. In the first step,
the parent chain is cleaved between amino acids
448 and 449. The result is one light chain (amino
acids 1-448, approx. 100 kDa) and one heavy chain
(amino acids 449-1295, approx. 100 kDa) connected
via a disulphide bond. The light chain is associated
with one atom of zinc9. In this form, the toxin
enters the axon terminal. The second activating
step, disulphide reduction, occurs only after
internalisation by the target cell.
2.1.1 Mechanism of Botulinum Toxin Action
The primary target site of botulinum toxin is
the cholinergic nerve ending of the neuromuscular
junction, where the toxin binds rapidly and prevents
the release of acetylcholine. There are three steps
in the neurotoxic action of botulinum toxin. First,
the toxic protein attaches to the presynaptic nerve
membrane. Then, the toxin crosses the presynaptic
plasma membrane, following which the toxin inhibits
release of vesicle-bounded acetylcholine10. Once
bound to its receptor, botulinum toxin is productively
internalised by receptor-mediated endocytosis. However,
before it can act on its intracellular substrate, the
toxin must escape the endosomal compartment. During
this process, acidification of the endosome results
in rearrangement of the toxin and translocation
into the cytosol. The final stage of intoxication is
inactivation of an intracellular target essential for
transmitter release, leading to paralysis. The reason
that it is possible to produce sufficient weakness
of the muscle to prevent symptomatic spasm, but
not completely block voluntary control, may be
that more active neuromuscular junctions are more
likely to be blocked  than the less active junctions.
The toxin may also have some action on the central
nervous system. Botulinum toxin has been shown
to enter the central nervous system in animals by
retrograde axonal transport11
.
2.1.2 Botulinum Toxin Poisoning
There are the following three main kinds of
botulism:
• Foodborne botulism is caused by eating foods
that contain the botulism toxin.
• Wound botulism is caused by toxin produced
from a wound infected with Clostridium botulinum.
• Infant botulism is caused by consuming the
spores of the botulinum bacteria, which then
grow in the intestines and release toxin.
With foodborne botulism, symptoms begin within
6 hours to 2 weeks (most commonly between 12 h
and 36 h) after eating toxin-containing food. Symptoms
of botulism include double vision, blurred vision,
drooping eyelids, slurred speech, difficulty swallowing,
dry mouth, muscle weakness that always descends
through the body (first shoulders are affected, then
upper arms, lower arms, thighs, calves, etc). Paralysis
of breathing muscles can cause a person to stop
breathing and die, unless assistance with breathing
(mechanical ventilation) is provided. Botulism is
not spread from one person to another. Foodborne
botulism can occur in all age groups.
Wound botulism, caused by the growth of bacterial
cells and release of toxin in vivo, is associated
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with traumatic wounds and abscesses, and has been
reported in drug users such as those injecting heroin
or sniffing cocaine. This disease comes from an
infection caused by dirty work, dirty skin or dirty
drugs. Most patients have used black tar heroin.
Initial symptoms are drooping eyelids, blurred or
double vision, sore throat or trouble in swallowing.
This can lead to complete paralysis and death.
Infant botulism results from a unique infectious
disease pathway. Ingested spores of Clostridium
botulinum germinate, colonise the infant colon,
and produce botulinum neurotoxin in situ12,13. The
toxin is subsequently absorbed and carried by the
blood stream to peripheral cholinergic synapses,
where it binds irreversibly. The light chain is then
taken into the cytosol of the neuron, where it blocks
the release of acetylcholine by enzymatic cleavage
of fusion complex proteins14. Clinically, the most
important part of the peripheral cholinergic synapses
is the neuromuscular junction; the toxin's action
results in flaccid paralysis and hypotonia. Preganglionic
cholinergic synapses in the autonomic nervous system
may also be affected15.
3. DIAGNOSIS OF BOTULISM
Misdiagnosis of botulism is frequent16. It may
be confused with stroke, for example, Guillain-
Barré syndrome or myasthenia gravis. Several diagnostic
tests should therefore be performed to rule out
these other syndromes, since waiting for the definitive
diagnosis of botulism can take days, and patients
need to have treatment immediately. Diagnosis depends
on identifying the presence of toxin in blood samples,
using some form of antigen-antibody reaction. In
the natural disease, the bacterium and/or preformed
toxin may be identified in unconsumed food samples.
4. PROPHYLAXIS
Toxoid vaccines against the toxins of types A
to F have been produced and evaluated in animal
and human studies17. Type A toxoid has a product
licence in the UK. The present toxoid vaccines
require several doses over a period of several weeks
to produce protection. Primate studies have also
demonstrated passive protection against inhalation
or injection of toxin by equine or human immune
globulin. The level of protection depends entirely
on the stoichiometric relationship between the amount
of circulating antibody and the amount of toxin to
which an individual may have been exposed.
Vaccination provides a high degree of protection
and is commonly administered to laboratory
investigators who are at risk of exposure. The current
vaccine is pentavalent (A-E) and is available from
the Centres for Disease Control and Prevention
(CDC Atlanta, USA). The vaccine is administered
at 0, 2, and 12 week intervals and requires a booster
dose after 1 year to generate long-term protection.
A heptavalent vaccine (A-G) is under development
by the US Army. In addition, a vaccine made from
the recombined binding domain of butulinum toxin-
chain (C-fragment) is also under development18
.
5. STABILITY & NEUTRALISATION
Botulinum toxins are rather easily inactivated.
In food or drink, heating to 85 °C for more than
5 min is sufficient to detoxify the contaminated
food or drinks 19. In the airborne state, the botulinum
toxin is degraded by extremes of temperature or
humidity. The rate of decay of aerosolised toxin
has been estimated at 1-4 per cent per minute,
depending on the weather conditions. Contaminated
surfaces should be cleaned with 0.1 per cent
hypochlorite solution if these cannot be avoided
for the few hours to days that natural degradation
would require20.
6. TREATMENT OF BOTULISM
Emergency hospitalisation is recommended in
cases of respiratory problem. The treatment aims
to establish a clear airway, aid breathing, give
botulinum antitoxin, and provide supportive therapy21.
If breathing problem starts, intubation (a tube inserted
through the nose or mouth into the trachea to provide
an airway for oxygen) and mechanical ventilation
are given. Intravenous fluids can be given while
swallowing difficulties persist. Also, a feeding tube
may be inserted in the nose. Antibiotics are often
given, but have not been shown to be beneficial
always.
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Before the development of mechanical ventilators,
the respiratory paralysis caused by botulism claimed
many more lives than it does today. For example,
during 1910-1919, the death rate from botulism
was 70 per cent. By the 1980s, the death rate had
dropped to 9 per cent, and in 1993, it was less than
2 per cent. But recovery is still slow; assuming the
patient receives proper care to ensure continued
breathing, recovery occurs only when the affected
nerves grow new endings, a process that can take
several months, although the length of recovery
time varies greatly from case to case. Potassium
channel blockers were found to be more effective
in antagonising the paralytic action of botulinum
toxin. The most promising candidate is 3,4-DAP
(diaminopyridine).
7. POTENTIAL BIOLOGICAL WEAPONS
FOR MILITARY TERRORISTS
There is a heightened awareness of the threat
of biological weapons being used for biological
warfare or bioterrorism. Many toxins that may be
used biological weapons as such can easily be acquired
and mass-produced. Dissemination of aerosols of
these biological agents can produce mass casualties.
If used by terrorists, these may overwhelm our
current public health system.
Some biological agents, such as Bacillus anthracis
(anthrax) and botulinum toxin, are considered, far
more likely than others, to be used as biological
weapons22. The potential for intentional poisoning
with botulinum toxin has come into clearer focus
in recent years23,24. As many as 17 countries were
suspected to include or to be developing biological
agents in their offensive weapons25 programme in
1996, and at present, the number of countries is
probably even higher. Botulinum toxin often is
included as one of these agents because it is relatively
easy to produce and is highly lethal even in small
quantities. In August 1995, Iraq revealed that during
the Gulf War, 11,200 litre of botulinum toxin was
loaded into specially designed SCUD missile war-
heads 26. In addition, before the Aum Shinrikyo used
sarin in the 1995 terrorist attack on the Tokyo
subway system, the cult had produced botulinum
toxin27.
Research and production, and use of botulinum
toxin as a possible biological weapon began at
least 65 years ago28
. The Head of the Japanese
Biological Warfare Group (Unit 731) admitted to
feeding cultures of Clostridium botulinum with lethal
effect to prisoners during that country's occupation
of Manchuria29, which began in the 1930s. The US
biological weapons program first produced botulinum
toxin during World War II. Because of concern that
Germany had weaponised botulinum toxin, more
than 1 million doses of botulinum toxoid vaccine
were made for Allied troops preparing to invade
Normandy on D-Day30.
Although the Biological and Toxin Weapons
Convention (1972) prohibits offensive research and
production of biological weapons, signatories Iraq
and the Soviet Union subsequently produced botulinum
toxin for use as a weapon31. Botulinum toxin was
one of the several agents tested at the Soviet site
Aralsk-7 on Vozrozhdeniye island in the Aral sea32.
A former senior scientist of the Russian civilian
bioweapons program reported that the Soviets had
attempted splicing the botulinum toxin gene from
Clostridium botulinum into other bacteria33. With
the economic difficulties in Russia after the demise
of the Soviet Union, some out of the thousands of
scientists formerly employed by its bioweapons
programme were recruited by the nations attempting
to develop biological weapons34. Four of the countries
listed by the US Govt as state sponsors of terrorism
(Iran, Iraq, North Korea, and Syria) have developed,
or are believed to be developing, botulinum toxin
as a weapon35,36.
After the 1991 Gulf War, Iraq admitted to the
UN Inspection Team to having produced 19,000
litre of concentrated botulinum toxin, of which
approx. 10,000 litre were loaded into the military
weapons37. These 19,000 litre of concentrated toxin
are not fully accounted for and constitute approx.
3-times the quantity needed to kill the entire current
human population by inhalation of this toxin. In
1990, Iraq deployed specially-designed missiles
with a 600 km range; 13 of these were filled with
botulinum toxin, 10 with aflatoxin, and 2 with
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anthrax spores. Iraq also deployed special 180 kg
bombs for immediate use; 100 bombs contained
botulinum toxin, 50 bombs contained anthrax spores,
and 7 bombs contained aflatoxin37. It is noteworthy
that Iraq chose to weaponise more botulinum toxin
than any other of its known biological agents.
Some contemporary analyses discount the potential
of botulinum toxin as a toxin weapon because of
constraints in concentrating and stabilising the toxin
for aerosol dissemination. But the terrorist use of
botulinum toxin in the deliberate contamination of
food could produce either a large botulism outbreak
from a single meal or episodic, widely separated
outbreaks38. In the US, the CDC maintains a well-
established surveillance system for human botulism
based on clinician reporting that would promptly
detect such events39.
8. MEDICINAL USE OF BOTULINUM
TOXIN
The therapeutic effects in human beings are
primarily due to the blockade of peripheral
neuromuscular transmission40. Botulinum toxin therapy
is invasive but safe and effective for treating strabismus,
blepharospasm, hemifacial spasm, adductor spasmodic
dysphonia, jaw-closing oromandibular dystonia, and
cervical dystonia. It is also used to treat facial tics,
swallowing and speech difficulties, migraines, and
many other medical conditions. Botulinum toxin
is not curative in chronic neurological disorders.
The safety of botulinum toxin therapy during pregnancy
or lactation, breast feeding, and chronic use during
childhood is unknown as well as the long-term
effects of chronic treatment. Botulinum toxin should
be administered by committed interdisciplinary teams
of physicians and related healthcare professionals
with appropriate instrumentation. The physician
administering this drug should be trained in its use
and qualified to manage any complications.
Contraindications of the use of botulinum toxin
are allergy to the drug and infection or inflammation
at the proposed injection site. Relative contra-
indications include diseases of neuromuscular
transmission, coagulopathy, and inability of the
patient to cooperate.
8.1 Ophthalmic Disorders
Botulinum toxin is effective as an alternative
to surgery to regulate the eyes of selected patients
with congenital or acquired strabismus41
. The toxin
appears to be more effective in esotropia of small-
to-moderate angles than in exotropia, vertical deviations,
or large-angle deviations. Botulinum toxin may be
indicated in certain ocular conditions where surgery
is inappropriate such as acute thyroid ophthalmopathy.
Botulinum toxin may prevent contracture of
antagonist muscles in cases of extraocular muscle
palsy from which some recovery is expected. In
these cases, single binocular vision may be enabled
or enhanced during the recovery phase, and late
contractures, that would require surgery, may be
prevented.  Botulinum toxin is also effective in the
long-term management of patients with essential
blepharospasm, and it has become the treatment
of choice. Symptoms are controlled in most patients
by injecting the toxin in multiple sites in the periocular
and facial muscles42.
8.2 Neurological Disorders
Botulinum toxin treatment of neurological patients
requires proper identification of the pathologically
hyperactive muscles, preferably by electromyography.
In focal dystonias, most of which respond poorly
to conventional therapy, botulinum toxin injection
may be the treatment of choice. In more generalised
dystonias, however, oral medication may be tried
before botulinum toxin. In generalised disorders,
botulinum toxin injection is indicated only for the
treatment of particularly severe focal abnormalities,
because injection of multiple muscle groups would
require unacceptably high doses of toxin43. Botulinum
toxin is an accepted therapy of cervical dystonia
(spasmodic torticollis), characterised by asymmetric
muscle spasms in the neck and oromandibular dystonia
(orofacial dyskinesia, Meige syndrome) consists
of continuous, bilateral, asynchronous spasms of
muscles of the face, jaw, pharynx, tongue, and, in
some severe cases, neck, larynx, and respiratory
system 44. Palliation with repeated injections of
botulinum toxin may be appropriate and effective
also in hemifacial spasm45.
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8.3 Voice & Speech Disorders
Botulinum toxin therapy for voice and speech
disorders requires the involvement of an interdisciplinary
team, including an otolaryngologist, a speech-language
pathologist, a neurologist, and a physician skilled
in regional electromyography. Voice laboratory facilities
should be available to assure valid diagnosis and
to document and quantify voice and speech function
before and following the treatment46,47.
9. COSMETIC USE OF BOTULINUM
TOXIN
Botulinum toxin A has had a lot of publicity
recently for its cosmetic use in facial wrinkles48
and makes beneficial poisoning49.  Botulinum toxin
type A is frequently used to smooth hyperkinetic
lines in the periocular and forehead areas of the
upper face, but it has been used less frequently for
indications in the lower face and neck50. Small
doses of the toxin are injected into the affected
muscles. As happens with botulism, the toxin binds
to the nerve endings, blocking the release of the
chemical acetylcholine, which would otherwise signal
the muscle to contract. The toxin thus paralyses or
weakens the injected muscle but leaves the other
muscles unaffected. The injections have been shown
to be generally safe. But, those wrinkles will come
back. The effects of the treatment are temporary and
it is possible to repeat it after about half-a-year.
10. CONCLUSIONS
Botulism-causing Clostridium botulinum bacteria
and their spores are found everywhere. Prevalent
in soil and marine sediments worldwide, their spores
are often found on the surfaces of fruits and vegetables,
and in seafood. The bacteria and spores themselves
are harmless; the dangerous substance is the toxin
produced by the bacteria when they grow. There
are seven varieties of botulinum toxin, designated
by the letters A through G. Botulinum toxin is the
most poisonous substance known. Once in the body,
the toxin binds to nerve endings at the point where
the nerves join muscles. This prevents the nerves
from signaling the muscles to contract. The result
is weakness and paralysis that descends from the
cranium down, affecting, among other things, the
muscles that regulate breathing. Respiratory failure,
secondary to paralysis of the respiratory muscles,
can lead to death unless appropriate therapy is
promptly initiated. Due to the severity and potency
of this neurotoxin, its importance as a biological
weapon is of major concern to public health officials.
The use of botulinum toxin as a medicinal agent
for correcting cholinergic disorders is very promising51.
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